Allergy Asthma Immunol Res.  2014 Mar;6(2):183-185. 10.4168/aair.2014.6.2.183.

A Case of Serum Sickness-Like Reaction and Anaphylaxis - Induced Simultaneously by Rifampin

• Kim DH
• Choi YH
• Kim HS
• Yu JE
• Koh YI

• KMID: 2260266
• DOI: http://doi.org/10.4168/aair.2014.6.2.183

Abstract

Rifampin is commonly used as a first-line anti-tuberculosis drug, but it can induce a serum sickness-like reaction or anaphylaxis. However, it is possible for 1 drug antigen to induce 2 or more simultaneous immunologic reactions. Here, we report a case of a serum-sickness-like reaction and anaphylaxis induced concurrently by rifampin. A 25-year-old male presented with high fever and a maculopapular rash with vesicles on the hands, which developed 2 weeks following regular administration of anti-tuberculosis drugs for tuberculous meningitis, including rifampin. Elevated liver enzymes, peripheral neuropathy, and decreased serum C3 and C4 levels were found. Interestingly, these symptoms were accompanied by severe hypotension. A serum-sickness-like reaction was considered after excluding other potential causes for the fever. A drug provocation test showed that the fever developed after oral administration of rifampin, suggesting that rifampin was the cause of the allergic reaction. However, hypotension, epigastric discomfort, and diarrhea also accompanied these symptoms, indicating that IgE-mediated type I hypersensitivity could be part of the serum sickness-like reaction. An intradermal skin test clearly showed an immediate positive reaction to rifampin. This case was diagnosed as concurrent serum-sickness-like reaction and anaphylaxis induced by rifampin. One drug may therefore induce combined allergic reactions via 2 or more simultaneous hypersensitivity responses.

Keyword

Rifampin; serum sickness, anaphylaxis

MeSH Terms

Administration, Oral
Adult
Anaphylaxis*
Diarrhea
Exanthema
Fever
Hand
Humans
Hypersensitivity
Hypersensitivity, Immediate
Hypotension
Liver
Male
Peripheral Nervous System Diseases
Rifampin*
Skin Tests
Tuberculosis, Meningeal
Rifampin

Figure

• 

  Fig. 1 Rifampin challenge test.

• 

  Fig. 2 The ratio of rifampin-induced mean wheal diameter to histamine-induced mean wheal diameter according to rifampin concentration in 9 normal controls. Data are expressed as means±SD.

Reference

1. Anderson JA. Allergic reactions to drugs and biological agents. JAMA. 1992; 268:2844–2857.

2. Safirstein BH, D'Souza MF, Simon G, Tai EH, Pepys J. Five-year follow-up of allergic bronchopulmonary aspergillosis. Am Rev Respir Dis. 1973; 108:450–459.

3. Ando M. Type III and type IV allergy: summer-type hypersensitivity pneumonitis. Jpn J Med. 1989; 28:548–549.

4. Demoly P, Bousquet J, Romano A. In vivo methods for the study of allergy. In : Adkinson NF, Bochner BS, Busse WW, Holgate ST, Lemanske RF, Simons FE, editors. Middleton's allergy: principles and practice. 7th ed. Philadelphia (PA): Mosby Elsevier;2009. p. 1267–1279.

5. Brož P, Harr T, Hecking C, Grize L, Scherer K, Jaeger KA, Bircher AJ. Nonirritant intradermal skin test concentrations of ciprofloxacin, clarithromycin, and rifampicin. Allergy. 2012; 67:647–652.

6. Lawley TJ, Bielory L, Gascon P, Yancey KB, Young NS, Frank MM. A prospective clinical and immunologic analysis of patients with serum sickness. N Engl J Med. 1984; 311:1407–1413.

7. Bielory L, Yancey KB, Young NS, Frank MM, Lawley TJ. Cutaneous manifestations of serum sickness in patients receiving antithymocyte globulin. J Am Acad Dermatol. 1985; 13:411–417.

8. Perrillo RP, Pohl DA, Roodman ST, Tsai CC. Acute non-A, non-B hepatitis with serum sickness-like syndrome and aplastic anemia. JAMA. 1981; 245:494–496.

9. McLeod JG. Investigation of peripheral neuropathy. J Neurol Neurosurg Psychiatry. 1995; 58:274–283.

10. Parra FM, Pérez Elias MJ, Cuevas M, Ferreira A. Serum sickness-like illness associated with rifampicin. Ann Allergy. 1994; 73:123–125.

11. Harland RW, Lindblom SS, Munnell MO. Anaphylaxis from rifampin. Am J Med. 1992; 92:581–582.

12. Namisato M, Ogawa H. Serious side effects of rifampin on the course of WHO/MDT: a case report. Int J Lepr Other Mycobact Dis. 2000; 68:277–282.

13. Luzzati R, Giacomazzi D, Franchi F, Barcobello M, Vento S. Life-threatening, multiple hypersensitivity reactions induced by rifampicin in one patient with pulmonary tuberculosis. South Med J. 2007; 100:854–856.